Publicacións en colaboración con investigadores/as de Stanford University School of Medicine (42)

2024

  1. European Society for Organ Transplantation (ESOT) Consensus Statement on the Use of Non-invasive Biomarkers for Cardiothoracic Transplant Rejection Surveillance

    Transplant International , Vol. 37

  2. Factors Associated With Coronary Angiography Performed Within 6 Months of Randomization to the Conservative Strategy in the ISCHEMIA Trial

    Circulation: Cardiovascular Interventions, Vol. 17, Núm. 6, pp. 457-473

  3. Global Longitudinal Strain as Predictor of Inducible Ischemia in No Obstructive Coronary Artery Disease in the CIAO-ISCHEMIA Study

    Journal of the American Society of Echocardiography, Vol. 37, Núm. 1, pp. 89-99

  4. Ischemia Severity, Coronary Artery Disease Extent, and Exercise Capacity in ISCHEMIA

    Circulation, Vol. 150, Núm. 2, pp. 165-167

  5. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

    Journal of Extracellular Vesicles, Vol. 13, Núm. 2

2023

  1. Donor heart selection: Evidence-based guidelines for providers

    Journal of Heart and Lung Transplantation, Vol. 42, Núm. 1, pp. 7-29

  2. Impact of Complete Revascularization in the ISCHEMIA Trial

    Journal of the American College of Cardiology, Vol. 82, Núm. 12, pp. 1175-1188

  3. Influence of Otolaryngological Subspecialties on Perception of Transoral Robotic Surgery: An International YO-IFOS Survey

    Journal of Personalized Medicine, Vol. 13, Núm. 12

  4. Survival after Invasive or Conservative Management of Stable Coronary Disease

    Circulation, Vol. 147, Núm. 1, pp. 8-19

2022

  1. A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function

    Kidney International, Vol. 101, Núm. 1, pp. 174-184

  2. Causes of cardiovascular and noncardiovascular death in the ISCHEMIA trial

    American Heart Journal, Vol. 248, pp. 72-83

  3. Effects of initial invasive vs. initial conservative treatment strategies on recurrent and total cardiovascular events in the ISCHEMIA trial

    European heart journal, Vol. 43, Núm. 2, pp. 148-149

  4. Heart transplantation: focus on donor recovery strategies, left ventricular assist devices, and novel therapies

    European heart journal, Vol. 43, Núm. 23, pp. 2237-2246

  5. Indications, Complications, and Outcomes of Cardiac Surgery After Heart Transplantation: Results From the Cash Study

    Frontiers in Cardiovascular Medicine, Vol. 10

  6. Natural History of MYH7-Related Dilated Cardiomyopathy

    Journal of the American College of Cardiology, Vol. 80, Núm. 15, pp. 1447-1461

  7. Outcomes With Intermediate Left Main Disease: Analysis From the ISCHEMIA Trial

    Circulation: Cardiovascular Interventions, Vol. 15, Núm. 4, pp. E010925

  8. Predictors of Left Main Coronary Artery Disease in the ISCHEMIA Trial

    Journal of the American College of Cardiology, Vol. 79, Núm. 7, pp. 651-661

  9. Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective analysis

    The Lancet Respiratory Medicine, Vol. 10, Núm. 4, pp. 367-377

2021

  1. Comparison of Days Alive out of Hospital with Initial Invasive vs Conservative Management: A Prespecified Analysis of the ISCHEMIA Trial

    JAMA Cardiology, Vol. 6, Núm. 9, pp. 1023-1031

  2. Effects of dapagliflozin on mortality in patients with chronic kidney disease: A pre-specified analysis from the DAPA-CKD randomized controlled trial

    European Heart Journal, Vol. 42, Núm. 13, pp. 1216-1227